Sglt 2 denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for sglt2 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny an SGLT2 Inhibitor as "Duplicate Therapy"

Aetna's duplicate-therapy denial for an SGLT2 inhibitor typically occurs when the plan's pharmacy system detects that the patient is already covered for another drug it considers therapeutically equivalent — often another SGLT2 inhibitor already on file, or in some cases a drug in a closely related class that the plan groups together under the same therapy category.

This denial is frequently incorrect or over-broad: SGLT2 inhibitors are not all identical in their FDA-approved indications. Different agents in this class carry distinct approvals for conditions such as type 2 diabetes, heart failure, and chronic kidney disease. A denial based on "duplicate therapy" may ignore clinically meaningful differences between agents.

## Federal Appeal Framework

• Internal appeal — file within the deadline stated on your denial notice. Aetna must decide standard pre-service appeals within 15 days (urgent) or 30 days (standard) for ERISA plans.
• External review (ACA §2719 / ERISA §503) — if your internal appeal is denied, independent external review is available, generally within approximately four months of the original adverse determination. Expedited review is available for urgent situations.

## Documentation to Gather

• FDA-approved prescribing labels — obtain the label for the prescribed SGLT2 inhibitor and, if applicable, the label for the drug Aetna considers a duplicate. Compare their approved indications side by side.
• Aetna's current published clinical policy for SGLT2 inhibitors — identify how the plan defines "duplicate therapy" and what exception criteria exist.
• Prescriber letter of medical necessity — the prescriber should explain the specific FDA-approved indication being treated, why the prescribed agent is the appropriate choice for this patient's clinical profile, and how it differs from any drug Aetna identified as a duplicate.
• Diagnosis and comorbidity documentation — chart notes confirming the condition(s) being treated, especially if the prescribed agent carries an indication relevant to a comorbidity (e.g., heart failure, CKD) that the alternative agent does not.
• Prior-treatment and response history — if the patient previously tried the drug Aetna considers equivalent and had an inadequate response or tolerability issue, document this with dates and outcomes.

## Criteria-Mapping Structure

| Question | Evidence | |---|---| | What indication is being treated? | [Diagnosis + ICD-10 + chart date] | | Does the prescribed agent carry that specific FDA approval? | [Label citation] | | Does the "duplicate" drug carry the same FDA approval for this indication? | [Label comparison] | | Is there a clinical reason to prefer the prescribed agent? | [Prescriber note] |

## Key Argument

Two drugs in the same class are not automatically duplicates if their FDA-approved indications differ. The appeal should demonstrate that the prescribed SGLT2 inhibitor is the appropriate agent for the specific indication being treated, and that any drug Aetna identified as a therapeutic equivalent either lacks that indication or is otherwise clinically unsuitable for this patient.